An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140203 T Cells and Determine the Recommended Phase II Dose (RP2D) in Adults With Advanced Hepatocellular Carcinoma (HCC) (ARYA-1)

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 11 Apr 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ET1402L1 CART (Primary)
Indications Hepatoblastoma; Liver cancer
Focus Adverse reactions
Acronyms ARYA-1
Sponsors Eureka Therapeutics

Most Recent Events

03 Apr 2024 Status changed from recruiting to discontinued for directing efforts to the pediatric study (ARYA-2) for this product.
12 Feb 2024 Planned End Date changed from 1 Jun 2024 to 1 Jun 2026.
12 Feb 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Apr 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight